Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ventyx Biosciences Inc (VTYX)

Ventyx Biosciences Inc (VTYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,001,784
  • Shares Outstanding, K 71,761
  • Annual Sales, $ 0 K
  • Annual Income, $ -135,120 K
  • EBIT $ -117 M
  • EBITDA $ -115 M
  • 60-Month Beta 1.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.19

Options Overview Details

View History
  • Implied Volatility 57.82% (+11.84%)
  • Historical Volatility 118.50%
  • IV Percentile 6%
  • IV Rank 4.72%
  • IV High 796.79% on 04/07/25
  • IV Low 21.19% on 01/23/26
  • Expected Move (DTE 11) 0.04 (0.30%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 3,330
  • Volume Avg (30-Day) 5,740
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 126,377
  • Open Int (30-Day) 105,402
  • Expected Range 13.92 to 14.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 4
  • High Estimate -0.32
  • Low Estimate -0.49
  • Prior Year -0.41
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.43 +3.95%
on 01/07/26
15.34 -9.00%
on 01/07/26
+3.91 (+38.91%)
since 01/06/26
3-Month
7.08 +97.18%
on 01/06/26
25.00 -44.16%
on 01/06/26
+4.70 (+50.76%)
since 11/06/25
52-Week
0.78 +1,682.89%
on 04/07/25
25.00 -44.16%
on 01/06/26
+12.17 (+679.89%)
since 02/06/25

Most Recent Stories

More News
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Ventyx Biosciences...

VTYX : 13.96 (+0.14%)
LLY : 1,058.18 (+3.66%)
Halper Sadeh LLC Encourages STEL, GORO, SKYT, VTYX Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

GORO : 1.5900 (+3.92%)
SKYT : 30.35 (+6.68%)
VTYX : 13.96 (+0.14%)
STEL : 39.17 (+1.21%)
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--SKYT, GORO, STEL, and VTYX

NEW YORK , Feb. 4, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

GORO : 1.5900 (+3.92%)
SKYT : 30.35 (+6.68%)
VTYX : 13.96 (+0.14%)
STEL : 39.17 (+1.21%)
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

NEW YORK and NEW ORLEANS , Jan. 23, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating...

VTYX : 13.96 (+0.14%)
LLY : 1,058.18 (+3.66%)
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VTYX, ALEX, RVYL, and FFWM

NEW YORK , Jan. 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

ALEX : 20.76 (unch)
RVYL : 6.89 (+29.76%)
VTYX : 13.96 (+0.14%)
FFWM : 6.43 (+0.16%)
Halper Sadeh LLC Encourages SEE, VTYX, SNCY Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

SEE : 41.82 (+0.07%)
VTYX : 13.96 (+0.14%)
SNCY : 21.84 (+12.58%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX). Such investors are...

VTYX : 13.96 (+0.14%)
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.

VTYX : 13.96 (+0.14%)
NVO : 47.64 (+9.92%)
LLY : 1,058.18 (+3.66%)
Halper Sadeh LLC Encourages VTYX, SNCY, EKSO Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

EKSO : 10.41 (+11.22%)
VTYX : 13.96 (+0.14%)
SNCY : 21.84 (+12.58%)
Halper Sadeh LLC Encourages VTYX, FONR, SNCY, FFIC Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

VTYX : 13.96 (+0.14%)
SNCY : 21.84 (+12.58%)
FFIC : 16.84 (+0.90%)
FONR : 18.56 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on advancing new therapies for patients living with inflammatory diseases and autoimmune disorders. The company's clinical stage pipeline includes VTX958, VTX002 and VTX2735. Ventyx Biosciences Inc. is headquartered in...

See More

Key Turning Points

3rd Resistance Point 14.03
2nd Resistance Point 13.99
1st Resistance Point 13.98
Last Price 13.96
1st Support Level 13.93
2nd Support Level 13.89
3rd Support Level 13.88

See More

52-Week High 25.00
Fibonacci 61.8% 15.75
Last Price 13.96
Fibonacci 50% 12.89
Fibonacci 38.2% 10.03
52-Week Low 0.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar